Diacerein for osteoarthritis

Fidelix, Tania; Macedo, Cristiane R; Maxwell, Lara; Trevisani, Virgínia Fernandes Moça

doi:10.1002/14651858.cd005117.pub3

Cited by 119 publications

(66 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Анализ результатов терапии 2069 пациентов показал достоверное уменьше-ние боли по сравнению с плацебо у больных гонартрозом и коксартрозом, при этом у последних отмечено структур-но-модифицирующее действие препарата [28].…”

Section: обсуждение основного результата исследованияunclassified

The analysis of efficacy of the use of inhibitor interleukin-1 in the complex therapy of secondary osteoarthritis taking into account the dynamics of clinical and functional indicators

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: обсуждение основного результата исследованияunclassified

The analysis of efficacy of the use of inhibitor interleukin-1 in the complex therapy of secondary osteoarthritis taking into account the dynamics of clinical and functional indicators

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Частота диареи в 1-й группе была сопоставима с результатами международных клинических исследований по эффективности и переносимости диацереина [25,26].…”

Section: материал и методыunclassified

Diacerein as the Drug of Choice in the Therapy of Knee Osteoarthritis With Secondary Recurrent Synovitis

Udovika¹

2015

rsp

View full text Add to dashboard Cite

“…Rhein is thought to act via inhibition of interleukin-1β and proteolytic enzymes along with which it stimulates the synthesis of cartilage components and modifies the understanding pathological conditions. As it does not inhibit the synthesis of prostaglandins is emerging as better and safe therapeutic agent as compared to NSAIDs 22,23 . It belongs to BCS class II with poor aqueous solubility (3.197mg/ml) 24 .…”

mentioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

ABSTRACT:Diacerein is an Osteoarthritic drug that exhibited suboptimal oral bioavailability upon oral administration of conventional dosage form. Nanosuspension gaining more attention for improving oral bioavailability of such drugs. This study was aimed to enhance the solubility and dissolution of diacerein by preparing Nanosuspension. Diacerein Nanosuspension was prepared using combination of High Speed Homogenization (HSH) and Media Milling (MM), Poloxamer 407 (stabilizer) and ZrO 2 beads (milling media). Various formulation and processing parameters were optimized in preliminary studies. Concentration of stabilizer and milling media were optimized for Cumulative percentage release (%CPR), saturation solubility (SS) and mean particle size (MPS) using 3 2 full factorial design. Optimized batch was derived statistically using desirability function of Minitab17. Model was validated by formulating checkpoint batch. Accelerated stability study was carried out for optimized batch. Identification and compatibility study of drug and stabilizers were carried out using FTIR and DSC studies. Preliminary parameters were optimized by varying one parameter at a time, while keeping other constant by trial and error method. Optimized batch has 100%w/v milling media and 1%w/v of Poloxamer407. %CPR, SS and MPS were found to be 97.74%, 1.245mg/ml and 221.5nm respectively. Four hundred times enhancement in SS that of bulk drug and 97.74%CPR at 2min was observed after nanonization. It was concluded that Combination of HSH and MM technique can be successfully used for preparation of Diacerein Nanosuspension. Prepared nanosuspension significantly enhances solubility and in-vitro dissolution of Diacerein.

show abstract

Diacerein for osteoarthritis

Cited by 119 publications

References 38 publications

The analysis of efficacy of the use of inhibitor interleukin-1 in the complex therapy of secondary osteoarthritis taking into account the dynamics of clinical and functional indicators

The analysis of efficacy of the use of inhibitor interleukin-1 in the complex therapy of secondary osteoarthritis taking into account the dynamics of clinical and functional indicators

Diacerein as the Drug of Choice in the Therapy of Knee Osteoarthritis With Secondary Recurrent Synovitis

Untitled

Contact Info

Product

Resources

About